Selsted ME, Novotny MJ, Morris WL, Tang YQ, Smith W, Cullor JS. 1992. Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils. The Journal of Biological Chemistry, 267(7): 4292-4295.
[2]
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. 2006. EUCAST technical note on tigecycline. Clinical Microbiology and Infection, 12(11): 1147-1149.
[3]
Thévenet P, Shen YM, Maupetit J, Guyon F, Derreumaux P, Tufféry P. 2012. PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Research, 40(W1): W288-293.
[4]
Thomas-Virnig CL, Centanni JM, Johnston CE, He LK, Schlosser SJ, Van Winkle KF, Chen RB, Gibson AL, Szilagyi A, Li LJ, Shankar R, Allen-Hoffmann BL. 2009. Inhibition of multidrug-resistant Acinetobacter baumannii by nonviral expression of hCAP-18 in a bioengineered human skin tissue. Molecular Therapy, 17(3): 562-569.
[5]
Vaara M. 2009. New approaches in peptide antibiotics. Current Opinion in Pharmacology, 9(5): 571-576.
[6]
Wang G, Li X, Wang Z. 2009. APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Research, 37(Database issue): D933-D937.
[7]
Wang YP, Hong J, Liu XH, Yang HL, Liu R, Wu J, Wang AL, Lin DH, Lai R. 2008. Snake cathelicidin from Bungarus fasciatus is a potent peptide antibiotics. PLos One, 3(9): e3127.
[8]
Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nature Reviews Microbiology, 3(3): 238-250.
[9]
Chromek M, Slamová Z, Bergman P, Kovács L, Podracká L, Ehrén I, H？kfelt T, Gudmundsson GH, Gallo RL, Agerberth B, Brauner A. 2006. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nature Medicine, 12(6): 636-641.
[10]
Cirioni O, Ghiselli R, Silvestri C, Kamysz W, Orlando F, Mocchegiani F, Di Matteo F, Riva A, ?ukasiak J, Scalise G, Saba V, Giacometti A. 2007. Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain. Antimicrobial Agents and Chemotherapy, 51(6): 2005-2010.
[11]
Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. M100-S23. Wayne, PA.
[12]
Conlon JM, Ahmed E, Condamine E. 2009. Antimicrobial properties of brevinin-2-related peptide and its analogs: Efficacy against multidrug-resistant Acinetobacter baumannii. Chemical Biology & Drug Design, 74(5): 488-493.
[13]
Conlon JM, Ahmed E, Pal T, Sonnevend A. 2010. Potent and rapid bactericidal action of alyteserin-1c and its [E4K] analog against multidrug-resistant strains of Acinetobacter baumannii. Peptides, 31(10): 1806-1810.
[14]
Falagas ME, Karageorgopoulos DE. 2008. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clinical Infectious Diseases, 46(7): 1121-1122.
[15]
Giacometti A, Cirioni O, Kamysz W, D''Amato G, Silvestri C, Del Prete MS, ?ukasiak J, Scalise G. 2003. Comparative activities of cecropin A, melittin, and cecropin A-melittin peptide CA(1-7)M(2-9)NH2 against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. Peptides, 24(9): 1315-1318.
[16]
Giacometti A, Cirioni O, Kamysz W, D''Amato G, Silvestri C, Del Prete MS, Licci A, Riva A, ?ukasiak J, Scalise G. 2005. In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients. Antimicrobial Agents and Chemotherapy, 49(3): 1249-1252.
[17]
Halverson T, Basir YJ, Knoop FC, Conlon JM. 2000. Purification and characterization of antimicrobial peptides from the skin of the North American green frog Rana clamitans. Peptides, 21(4): 469-476.
[18]
Hancock RE, Sahl HG. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature Biotechnology, 24(12): 1551-1557.
Knappe D, Piantavigna S, Hansen A, Mechler A, Binas A, Nolte O, Martin LL, Hoffmann R. 2010. Oncocin (VDKPPYLPRPRPPRRI YNR-NH2): a novel antibacterial peptide optimized against gram-negative human pathogens. Journal of Medicinal Chemistry, 53(14): 5240-5247.
[21]
Lipsky BA, Holroyd KJ, Zasloff M. 2008. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clinical Infectious Diseases, 47(12): 1537-1545.
[22]
Ouellette AJ, Miller SI, Henschen AH, Selsted ME. 1992. Purification and primary structure of murine cryptdin-1, a Paneth cell defensin. FEBS Letters, 304(2-3): 146-148.
[23]
Pagès JM, Dimarcq JL, Quenin S, Hetru C. 2003. Thanatin activity on multidrug resistant clinical isolates of Enterobacter aerogenes and Klebsiella pneumoniae. International Journal of Antimicrobial Agents, 22(3): 265-269.
[24]
Routsias JG, Karagounis P, Parvulesku G, Legakis NJ, Tsakris A. 2010. In vitro bactericidal activity of human β-defensin 2 against nosocomial strains. Peptides, 31(9): 1654-1660.
